Voceryq wins accelerated approval for recurrent respiratory papillomatosis

FDA approval makes Voceryq the first U.S.-approved plasmid DNA-based immunotherapy. The open-label evidence is preliminary: 7 of 26 patients in the reported subgroup had no surgery through 12 months, and confirmatory evidence is required. Launch is expected in 2027; durable benefit and uptake are key follow-ups.